Arrhythmia Disorders News

Preeclampsia appeared to increase primiparous women’s risk for developing arrhythmia, according to results of a real-world study published in European Journal of Preventative Cardiology.

A pulsed field ablation system was associated with low rates of safety events and high rates of efficacy for patients with paroxysmal atrial fibrillation at 12 months, according to the results of the admIRE pivotal trial.

In patients with long QT syndrome, vigorous exercise did not appear to increase CV event risk vs. nonvigorous exercise regardless of age, sex or genotype, according to new data from the LIVE-LQTS study presented at Heart Rhythm 2024.

A novel lead for use in implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators exceeded the safety and efficacy thresholds in the LEADR trial, researchers reported at Heart Rhythm 2024.

Active cancer treatment is associated with increased risk for sudden cardiac death, especially among patients younger than 74 years old and those with a history of heart failure, results from a retrospective study showed.

Pulsed field ablation lowered the odds of high residual atrial arrhythmia burden compared with thermal ablation for patients with atrial fibrillation at 1 year, according to a subanalysis of the ADVENT trial presented at Heart Rhythm 2024.

A platform with a mapping system and a large-tip catheter with dual pulsed field and radiofrequency energies was noninferior to a conventional radiofrequency ablation system for treatment of persistent atrial fibrillation, data show.

Tailored ablation guided by AI was linked to better 1-year outcomes than pulmonary vein isolation alone for patients with persistent atrial fibrillation, according to the results of the TAILORED-AF trial presented at Heart Rhythm 2024.

In a real-world registry of patients with atrial fibrillation treated with a pulsed field ablation catheter, the system was associated with favorable 30-day outcomes, researchers reported at Heart Rhythm 2024.

A system including a leadless pacemaker and a subcutaneous implantable cardioverter defibrillator that wirelessly communicate with each other was safe in patients at risk for fatal ventricular arrhythmias at 6 months, researchers reported.